跳至主要内容
临床试验/NCT02095626
NCT02095626已完成2 期

Pilot Study to Investigate the Clinical Effect of Orally Inhaled AP301 on Treatment of Primary Graft Dysfunction (PGD) in Mechanically Ventilated Patients After Primary Lung Transplantation

Apeptico Forschung und Entwicklung GmbH1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2013年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
20
试验地点
1
主要终点
P/F ratio

研究概览

简要总结

The purpose of this study is to investigate the effect of orally inhaled AP-301 on primary graft dysfunction after lung transplantation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Being a male or female recipient on the AKH's waiting list for primary single or double LuTX
  • PGD score ≥ 1 within 72 hours after LuTX
  • Informed consent is available

排除标准

  • History of clinically relevant allergies or idiosyncrasies to AP301 or any other inactive ingredient(s) of the investigational product
  • Postoperative ECMO support
  • Paediatric /adolescent recipients (< 18 years)
  • Lobar transplantation
  • Retransplantation
  • Combined solid organ transplants
  • Participation in other drug trials

研究组 & 干预措施

AP301

Experimental

Treatment group

干预措施: AP-301 (Drug)

Saline solution

Placebo Comparator

干预措施: saline solution (Drug)

结局指标

主要结局

P/F ratio

时间窗: 7 days

The changes of the P/F ratio from T0 (time of PGD diagnosis) to day 7 of the treatment or to extubation of the patient

次要结局

  • EVLW(7 days or until extubation)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Study in Intensive Care Patients Regarding the... | 临床试验